OverviewSuggest Edit

Novavax is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. Novavax's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza and the Ebola virus.

TypePublic
Founded1987
HQGaithersburg, MD, US
Websitenovavax.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Sept 2019)168(-45%)
Job Openings118
Revenue (FY, 2020)$475.6 M(+2449%)
Share Price (May 2021)$176(-9%)
Cybersecurity ratingAMore

Key People/Management at Novavax

Stanley C. Erck

Stanley C. Erck

Director, President and CEO
Frank Czworka

Frank Czworka

Senior Vice President, Sales
Gregory Covino

Gregory Covino

Executive Vice President and Chief Financial Officer
Gregory M. Glenn

Gregory M. Glenn

President, Research and Development
Filip Dubovsky

Filip Dubovsky

Executive Vice President, Chief Medical Officer
Rick Crowley

Rick Crowley

Executive Vice President, Chief Operations Officer
Show more

Novavax Office Locations

Novavax has offices in Gaithersburg, Jevany and Uppsala
Gaithersburg, MD, US (HQ)
21 Firstfield Rd
Jevany, CZ
Bohumil 138
Uppsala, SE
109 Kungsgatan
Show all (3)

Novavax Financials and Metrics

Novavax Revenue

Novavax's revenue was reported to be $475.6 m in FY, 2020
USD

Revenue (FY, 2020)

475.6m

Net income (FY, 2020)

(418.3m)

EBIT (FY, 2020)

(416.7m)

Market capitalization (7-May-2021)

13.0b

Closing stock price (7-May-2021)

176.0

Cash (31-Dec-2020)

553.4m

EV

12.9b
Novavax's current market capitalization is $13 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

14.7m22.1m20.9m30.7m36.3m15.4m31.2m34.3m18.7m475.6m

Revenue growth, %

4182%50%(5%)47%18%(58%)

Cost of goods sold

7.0m14.7m8.2m15.0m

Gross profit

7.7m7.4m12.7m15.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

3.0m5.0m4.6m7.1m5.8m3.8m3.5m4.8m7.5m8.3m8.2m9.9m14.0m6.5m4.2m2.5m3.2m5.7m6.7m8.4m9.7m10.8m7.7m4.0m3.4m2.5m3.4m35.5m

Cost of goods sold

3.8m5.1m3.8m1.7m1.6m2.3m3.0m5.1m2.5m2.7m2.7m

Gross profit

856.0k2.0m1.9m2.1m1.9m2.5m4.4m3.2m7.4m11.3m3.8m

Gross profit Margin, %

18%28%33%55%54%53%60%38%75%81%58%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

14.1m17.4m119.5m32.3m93.1m144.4m106.3m70.2m78.8m553.4m

Accounts Receivable

2.0m1.0m1.9m7.5m2.3m233.0k7.5m262.0m

Prepaid Expenses

2.4m2.6m17.8m16.3m8.0m181.3m

Inventories

9.2m19.3m21.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(19.4m)(28.5m)(52.0m)(82.9m)(156.9m)(280.0m)(183.8m)(184.7m)(132.7m)(418.3m)

Depreciation and Amortization

1.6m1.7m2.6m4.4m6.0m8.5m9.8m8.2m5.7m4.9m

Accounts Payable

(2.7m)2.0m4.2m14.0m9.1m(4.8m)5.2m(6.7m)(11.5m)163.2m

Cash From Operating Activities

(23.6m)(18.2m)(45.4m)(87.1m)60.8m(255.5m)(138.7m)(184.8m)(136.6m)(42.5m)
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Novavax Operating Metrics

FY, 2016

Patents (US)

250

Phase I Trials Products

2

Phase II Trials Products

1

Phase III Trials Products

1
Show all operating metrics

Novavax Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Novavax Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Novavax Online and Social Media Presence

Embed Graph

Novavax Company Culture

  • CEO Rating

    D-

    60/100

Learn more on Comparably

Novavax News and Updates

Global Influenza Vaccines Market Report 2021-2027 Featuring Emerging Players - Moderna, Novavax, Daiichi Sankyo, & Versatope Therapeutics

DUBLIN, May 7, 2021 /PRNewswire/ -- The "Global Influenza Vaccines Market 2021 - 2027" report has been added to ResearchAndMarkets.com's offering. The number of people being vaccinated with influenza vaccines worldwide will reach 500 million by the year-end of 2027. The Report Analyses...

Global Vaccines Market Analysis Report 2021: Forecast to 2025 Featuring Sinopharm, Serum Institute, Novavax, Moderna, Mitsubishi Tanabe Pharma, Emergent BioSolutions, and CSL

Dublin, May 04, 2021 (GLOBE NEWSWIRE) -- The "Vaccines Market - Global Industry Analysis (2017 - 2020), Growth Trends and Market Forecast (2021 - 2025)" report has been added to ResearchAndMarkets.com's offering. The market will register a 10.2% CAGR during the forecast period of 2020 to 2025. The…

Novavax begins testing its COVID-19 vaccine candidate in teens

Shares of Novavax Inc. gained 0.6% in trading on Monday after the biotechnology firm said it has expanded its Phase 3 clinical trial for its COVID-19 vaccine candidate to include 12 to 17 year olds in the U.S. Novavax's experimental vaccine is currently being tested in a late-stage trial that began…

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the...

What Is Driving Novavax Stock?

NVAX stock has gained almost 50% over the last month and trades at levels of around $258. So what’s driving the surge in the stock? Firstly, Novavax’s Covid-19 shot, which has been delayed multiple times, is likely to start being deployed commercially in the coming weeks. The shot should be...

Will Novavax Stock Benefit From Johnson & Johnson’s Covid Vaccine Woes?

Novavax (NASDAQ: NVAX) stock rallied by over 10% after the U.S. Food and Drug Administration and the U.S. Centers for Disease Control paused the rollout of Johnson & Johnson’s Covid-19 vaccine in the U.S. following some rare, yet severe incidents of blood clotting.
Show more

Novavax Blogs

Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

Novavax Reports First Quarter 2021 Financial Results and Operational Highlights Michael.Fuccio… Mon, 05/10/2021 - 16:03 Novavax Reports First Quarter 2021 Financial Results and Operational Highlights May 10, 2021 at 4:02 PM EDT This release is a backfill from …

Novavax Statement on Updated PREVENT-19 Trial Protocol

Novavax Statement on Updated PREVENT-19 Trial Protocol jhansen@novavax.com Mon, 05/10/2021 - 15:55 Novavax Statement on Updated PREVENT-19 Trial Protocol May 10, 2021 at 3:59 PM EDT This release is a backfill from a News Wire Statement …

Novavax Statement in Opposition to the WTO TRIPS Waiver

Novavax is committed to accelerating equitable access to safe and effective COVID-19 vaccines, particularly in countries where vaccination rates are low. On May 6, 2021 we again demonstrated this commitment through the finalization of an advance purchase agreement with Gavi, which in conjunction

Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan

Today in a press conference, the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) provided an update on its ongoing efforts to secure coronavirus vaccine for the citizens of Japan. As part of these efforts, Takeda is in the process of establishing vaccine procurement based on

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

Novavax to deliver 350 million doses beginning Q3 2021 1.1 billion doses of Novavax vaccine to be available to countries participating in COVAX Serum Institute of India to provide balance of doses for LMICs Underscores commitment to global equitable access to Novavax vaccine GAITHERSBURG, Md.

New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

- Publication of initial primary analysis highlights NVX-CoV2373 cross-protection against B.1.351 variant prevalent in South Africa during study GAITHERSBURG, Md. , May 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious
Show more

Novavax Frequently Asked Questions

  • When was Novavax founded?

    Novavax was founded in 1987.

  • Who are Novavax key executives?

    Novavax's key executives are Stanley C. Erck, Frank Czworka and Gregory Covino.

  • How many employees does Novavax have?

    Novavax has 168 employees.

  • What is Novavax revenue?

    Latest Novavax annual revenue is $475.6 m.

  • What is Novavax revenue per employee?

    Latest Novavax revenue per employee is $2.8 m.

  • Who are Novavax competitors?

    Competitors of Novavax include Proteus Digital Health, CosmosID and TCR2 Therapeutics.

  • Where is Novavax headquarters?

    Novavax headquarters is located at 21 Firstfield Rd, Gaithersburg.

  • Where are Novavax offices?

    Novavax has offices in Gaithersburg, Jevany and Uppsala.

  • How many offices does Novavax have?

    Novavax has 3 offices.